FATE Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
Fate Therapeutics Inc had $6.6M of revenue in fiscal 2025, down 51.2% on the year before. Over five years, revenue changed β26.7% a year on average.
Last close Β· Oct 23, 2026
$2.11
1.0%Hi! I read Fate Therapeutics Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β51.2%
No. Sales fell 51.2% last year.
Does it make a profit?
β2,051.1%
No. It lost money last year.
Does profit turn into cash?
β1,685.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Fate Therapeutics Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 13, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Feb 26, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 13, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 7, 2025 | Q2 '25 | Time not announced | 8-K β |
| May 13, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 5, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 12, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Fate Therapeutics Inc had $6.6M of revenue in fiscal 2025, down 51.2% on the year before. Over five years, revenue changed β26.7% a year on average. Its operating margin was β2,222.4%, down 679.8Β pts: of every 100 in sales, about β2,222 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Fate Therapeutics Inc lost $136M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$112M in fiscal 2025, β1,685.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Fate Therapeutics Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $616M | $436M | $315M | $279M | $204M |
| Current ratio | 7.8x | 4.4x | 8.5x | 7.6x | 5.8x |
| Quick ratio | 7.8x | 4.4x | 8.5x | 7.6x | 5.8x |
| Total assets | $921M | $706M | $506M | $441M | $319M |
| Total liabilities | $243M | $222M | $138M | $122M | $112M |
| Shareholders' equity | $679M | $484M | $368M | $319M | $207M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Fate Therapeutics Inc passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 8 | 3 / 8 | 3 / 7 | 3 / 7 | 4 / 7 | 2 / 7 | 3 / 7 | 1 / 7 | 1 / 7 |
| Accruals ratio | β3.8% | β6.1% | β17.6% | β5.8% | β29.0% | β6.4% | β4.1% | β4.7% | β13.4% | β8.0% |
| Altman Z'' | 0.61 | β0.88 | 2.20 | 2.42 | 1.70 | 2.57 | β1.89 | β3.74 | β7.03 | β13.30 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $4.4M | $4.1M | $4.7M | $10.7M | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | $6.6M |
| Research and development | $26.5M | $34.4M | $56.0M | $87.8M | $126M | $216M | $320M | $173M | $135M | $108M |
| Operating income | β$32.0M | β$42.1M | β$67.1M | β$101M | β$128M | β$217M | β$308M | β$191M | β$210M | β$148M |
| Interest expense | $1.6M | $1.3M | $1.7M | $1.8M | $0.0M | $0.0M | β | β | β | β |
| Income tax | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$33.5M | β$43.0M | β$66.6M | β$98.1M | β$173M | β$212M | β$282M | β$161M | β$186M | β$136M |
| Diluted EPS | β$1.05 | β$1.02 | β$1.19 | β$1.44 | β$2.10 | β$2.24 | β$2.91 | β$1.64 | β$1.64 | β$1.15 |
| Diluted shares | 0.03B | 0.04B | 0.06B | 0.07B | 0.08B | 0.09B | 0.10B | 0.10B | 0.11B | 0.12B |
| Cash flow | ||||||||||
| Cash from operations | β$29.8M | β$36.8M | β$38.7M | β$83.2M | β$39.2M | β$163M | β$248M | β$132M | β$123M | β$106M |
| Capital expenditure | $0.5M | $1.7M | $2.3M | $7.4M | $4.9M | $50.7M | $35.6M | $6.2M | $0.7M | $6.0M |
| Free cash flow | β$30.3M | β$38.5M | β$41.0M | β$90.6M | β$44.2M | β$214M | β$284M | β$138M | β$124M | β$112M |
| Depreciation and amortization | $0.9M | $1.0M | $1.2M | $2.2M | $3.1M | $5.9M | $13.8M | $18.3M | $19.0M | $12.9M |
| Stock-based compensation | $3.2M | $3.6M | $6.3M | $17.4M | $30.8M | $54.4M | $78.7M | $43.5M | $41.5M | $24.9M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $92.1M | $89.0M | $191M | $99.8M | $167M | $616M | $436M | $315M | $279M | $204M |
| Total debt | $12.8M | $19.3M | $18.5M | β | β | β | β | β | β | β |
| Current assets | $93.3M | $103M | $205M | $227M | $494M | $633M | $502M | $332M | $292M | $209M |
| Current liabilities | $15.2M | $11.0M | $27.3M | $27.8M | $85.6M | $81.3M | $114M | $39.1M | $38.5M | $36.1M |
| Property and equipment, net | $1.6M | $2.6M | $5.1M | $11.4M | $32.3M | $91.5M | $110M | $96.8M | $64.4M | $56.9M |
| Total assets | $95.0M | $105M | $213M | $302M | $622M | $921M | $706M | $506M | $441M | $319M |
| Total liabilities | $21.9M | $28.1M | $52.6M | $57.5M | $238M | $243M | $222M | $138M | $122M | $112M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $73.2M | $77.2M | $160M | $245M | $384M | $679M | $484M | $368M | $319M | $207M |
| Margins | ||||||||||
| Operating margin | β726.1% | β1,025.9% | β1,415.4% | β943.1% | β407.5% | β388.6% | β320.2% | β299.9% | β1,542.6% | β2,222.4% |
| EBITDA margin | β706.1% | β1,002.3% | β1,390.0% | β922.6% | β397.7% | β378.1% | β305.9% | β271.1% | β1,403.5% | β2,028.3% |
| Net margin | β760.2% | β1,046.1% | β1,405.0% | β919.0% | β551.6% | β379.9% | β292.5% | β253.3% | β1,366.5% | β2,051.1% |
| FCF margin | β687.9% | β938.7% | β864.0% | β848.0% | β140.5% | β382.4% | β294.7% | β217.9% | β906.8% | β1,685.8% |
| Returns | ||||||||||
| Return on capital | β | β440.4% | β | β | β | β | β | β | β | β |
| Return on capital employed | β40.0% | β44.7% | β36.1% | β36.7% | β23.9% | β25.8% | β52.1% | β40.8% | β52.3% | β52.2% |
| Return on equity | β45.7% | β57.1% | β56.0% | β48.4% | β55.1% | β39.9% | β48.5% | β37.8% | β54.2% | β51.8% |
| Return on assets | β35.2% | β42.9% | β41.8% | β38.1% | β37.5% | β27.5% | β34.6% | β26.6% | β39.3% | β35.9% |
| Return on tangible equity | β45.7% | β55.6% | β41.5% | β40.1% | β45.1% | β31.3% | β58.2% | β43.7% | β58.4% | β65.8% |
| Growth | ||||||||||
| Revenue growth | β | β6.7% | 15.4% | 125.3% | 194.3% | 77.7% | 72.4% | β34.0% | β78.5% | β51.2% |
| Share count change | β | 32.2% | 33.9% | 21.3% | 20.8% | 15.0% | 2.2% | 1.6% | 15.5% | 4.5% |
| Financial health | ||||||||||
| Debt / equity | 0.2x | 0.3x | 0.1x | β | β | β | β | β | β | β |
| Interest coverage | β19.5x | β33.2x | β39.6x | β57.5x | β | β | β | β | β | β |
| Current ratio | 6.1x | 9.3x | 7.5x | 8.2x | 5.8x | 7.8x | 4.4x | 8.5x | 7.6x | 5.8x |
| Quick ratio | 6.1x | 9.3x | 7.5x | 8.2x | 5.8x | 7.8x | 4.4x | 8.5x | 7.6x | 5.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 10.4% | 42.0% | 48.6% | 69.2% | 15.7% | 90.8% | 36.9% | 9.7% | 5.4% | 89.6% |
| Stock comp / revenue | 72.3% | 87.8% | 132.8% | 163.0% | 97.8% | 97.3% | 81.8% | 68.4% | 304.4% | 375.0% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 3.0 | 3.0 | 3.0 | 4.0 | 2.0 | 3.0 | 1.0 | 1.0 |
| Altman Z'' | 0.6 | β0.9 | 2.2 | 2.4 | 1.7 | 2.6 | β1.9 | β3.7 | β7.0 | β13.3 |
| Accruals ratio | β3.8% | β6.1% | β17.6% | β5.8% | β29.0% | β6.4% | β4.1% | β4.7% | β13.4% | β8.0% |
Source: SEC EDGAR XBRL filings (CIK 0001434316). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
